TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05756556

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: T3011 + Cobimetinib
Description: 1e8 plaque-forming units (PFU)/mL (up to 10 mL, every 2 weeks \[Q2W\], 28 days/cycle) T3011 will be administered in combination with 60 mg Cobimetinib (once daily \[QD\] for the first 21 days of each 28-day cycle)
Study: NCT06110143

Intervention type: OTHER
Group type: OTHER
Intervention: Periodontal treatment
Description: Periodontal treatment

Intervention type: OTHER
Group type: OTHER
Intervention: Periodontal treatment
Description: Periodontal treatment
Study: NCT05031936

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: cervical spinal injection with 0.2% ropivacaine
Description: spinal injections performed in cervical pillar area to relieve chronic neck pain

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cervical spinal injection with 0.2% ropivacaine
Description: spinal injections performed in cervical pillar area to relieve chronic neck pain
Study: NCT06251726

Intervention type: DIAGNOSTIC_TEST
Intervention: Immunoscore Colon Test
Description: Immunoscore Colon is an in-vitro diagnostic test, allowing the quantification of CD3 and CD8 positive cells in formalin-fixed paraffin-embedded (FFPE) tissue samples of primary colon cancer.~The test uses immunohistochemistry, digital pathology techniques and a dedicated image analysis software to determine CD3+ and CD8 + cell densities in the tumor ant in the invasive margin of the tumor.
Study: NCT05926856

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indocyanine green
Description: Indocyanine Green 25mg kit for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine green
Description: Indocyanine Green 25mg kit for injection
Study: NCT06781983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPH4502
Description: Part 1 (dose escalation) and Part 2 (dose optimization)
Study: NCT06658899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRD-4730
Description: Oral CRD-4730 in tablet form

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match CRD-4730 in tablet form
Study: NCT05742724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrahydrocannabinol-Cannabidiol Combination
Description: Oral THC 0.1mg/kg and CBD 2.5mg/kg
Study: NCT04990310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-CORT113176
Description: \[14C\]-CORT113176 450 mg lipid formulation capsule for oral administration containing not more than 3.37 megaBequerel 14C.
Study: NCT06268353

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood sampling
Description: Measure CAPGDF15 in plasma of 3 pregnant and 3 non-pregnant women
Study: NCT05990920

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SNK02
Description: SNK02 is ex vivo expanded allogeneic NK cells for IV injection, is a light-yellow cryopreserved cell suspension consisting of NK cells isolated from healthy donor's peripheral blood mononuclear cells.
Study: NCT06258239

Intervention type: OTHER
Group type: OTHER
Intervention: Communication between nursing staff and participants
Description: The analgesic treatment that will be given are part of clinical routine - the participants will get the same exact treatment regardless if they entered the study and to which study arm they entered. The effect that we are interested to capture is the potential added value of communication between the nursing staff and participants while administrating analgesics.

Intervention type: OTHER
Group type: OTHER
Intervention: Communication between nursing staff and participants
Description: The analgesic treatment that will be given are part of clinical routine - the participants will get the same exact treatment regardless if they entered the study and to which study arm they entered. The effect that we are interested to capture is the potential added value of communication between the nursing staff and participants while administrating analgesics.
Study: NCT04640480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNB-101
Description: SN-38 dosage ranges from 1 to 7 will be determined by Safety Review Committee meeting

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNB-101
Description: SN-38 dosage ranges from 1 to 7 will be determined by Safety Review Committee meeting

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNB-101
Description: SN-38 dosage ranges from 1 to 7 will be determined by Safety Review Committee meeting

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNB-101
Description: SN-38 dosage ranges from 1 to 7 will be determined by Safety Review Committee meeting

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNB-101
Description: SN-38 dosage ranges from 1 to 7 will be determined by Safety Review Committee meeting

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNB-101
Description: SN-38 dosage ranges from 1 to 7 will be determined by Safety Review Committee meeting

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNB-101
Description: SN-38 dosage ranges from 1 to 7 will be determined by Safety Review Committee meeting
Study: NCT06666296

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Social-Media
Description: A dedicated Instagram account for this project will be created for the center, where valuable content on the Planetary Health Diet will be shared regularly. The test subjects can also use this platform to exchange information.
Study: NCT06474416

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: BD111 Injection (Investigative New Drug)
Description: BD111 Injection (Investigative New Drug) is a type of lentiviral-like particle, which can simultaneously deliver SpCas9 and gRNA targeting the HSV-1 virus gene, also known as HSV-1-erasing lentiviral particles (HELP).

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: BD111 Injection (Investigative New Drug)
Description: BD111 Injection (Investigative New Drug) is a type of lentiviral-like particle, which can simultaneously deliver SpCas9 and gRNA targeting the HSV-1 virus gene, also known as HSV-1-erasing lentiviral particles (HELP).

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: BD111 Injection (Investigative New Drug)
Description: BD111 Injection (Investigative New Drug) is a type of lentiviral-like particle, which can simultaneously deliver SpCas9 and gRNA targeting the HSV-1 virus gene, also known as HSV-1-erasing lentiviral particles (HELP).

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: BD111 Injection (Investigative New Drug)
Description: BD111 Injection (Investigative New Drug) is a type of lentiviral-like particle, which can simultaneously deliver SpCas9 and gRNA targeting the HSV-1 virus gene, also known as HSV-1-erasing lentiviral particles (HELP).

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Triple-drugs therapy of HSV-1 stromal keratitis
Description: Triple-drugs therapy: Ganciclovir Eye gel+Valacilovir Tablets+Prednisolone Acetate Eye Drops for 3 weeks.
Study: NCT02127684

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab
Description: ranibizumab 0.3mg intravitreally monthly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab
Description: ranibizumab given every 2 weeks for 8 weeks then monthly as needed
Study: NCT05631574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMF-219
Description: BMF-219 is an orally bioavailable, covalent small-molecule menin inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMF-219
Description: BMF-219 is an orally bioavailable, covalent small-molecule menin inhibitor.
Study: NCT06781931

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DG1 Spectacle Lens
Description: DG1 spectacle lens, daily wear for 36 months

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Single Vision Spectacle Lens
Description: Single vision spectacle lens, daily wear for 36 months
Study: NCT06781801

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention
Description: The intervention group follows a structured flowchart for annual health check-ups, focusing on assessing the cardiometabolic profile, considering sex and ethnicity. This assessment includes tracking changes in cardiometabolic parameters, alongside overall cardiometabolic risk using SCORE2 and if the criteria for metabolic syndrome are met.~Lifestyle habits are evaluated based on health status, illness, and benefits of quitting unhealthy behaviors. Education sessions educate participants and families on the link between psychotic disorders, lifestyle choices, and cardiometabolic health.~Gradual lifestyle changes are tailored to individual needs, addressing stress and cognitive challenges, and follow national health guidelines with personalized advice and motivational tools. Regular follow-ups assess progress, while motivational tools body composition analyzer and QRISK3 enhance engagement. Contact with internal and external resources is based on the assessment and motivational work.
Study: NCT06780410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bempedoic Acid Tablet
Description: Once daily, oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily, oral
Study: NCT06040892

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: SPHERE protocol : Spatial hearing performances test
Description: Participants will be instructed to localize a sound emitted in their environment using a virtual reality setup (SPHERE protocol).
Study: NCT06666296

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social-Media
Description: A dedicated Instagram account for this project will be created for the center, where valuable content on the Planetary Health Diet will be shared regularly. The test subjects can also use this platform to exchange information.
Study: NCT04699188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JDQ443
Description: KRAS G12C inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JDQ443
Description: KRAS G12C inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JDQ443
Description: KRAS G12C inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JDQ443
Description: KRAS G12C inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNO155
Description: SHP2 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNO155
Description: SHP2 inhibitor

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tislelizumab
Description: Anti PD1 antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tislelizumab
Description: Anti PD1 antibody
Study: NCT04746430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 6 mg dexamethasone prescribed during ten days and as a precaution combined with electronic monitoring of saturation and other signs and symptoms
Study: NCT06667336

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intermittent suction
Description: This suction was applied only as needed to clear secretions

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: continuous suction
Description: The suction catheter was inserted at the start of laryngoscopy and maintained in the oropharynx until the moment of ETT delivery.
Study: NCT06667557

Intervention type: DEVICE
Intervention: Superpulse Thulium Fiber Laser (sTFL) Treatment
Description: The superpulse thulium fiber laser (sTFL) was used as a minimally invasive surgical treatment for kidney and upper ureteral stones. All procedures were performed by experienced urologists using standard techniques for laser lithotripsy. Laser settings, such as pulse energy and frequency, were adjusted according to stone characteristics and the surgeon's judgment to optimize treatment efficacy and safety.

Intervention type: DEVICE
Intervention: Holmium:YAG Laser (Ho:YAG) Treatment
Description: The holmium:YAG laser (Ho:YAG) was used as a minimally invasive surgical treatment for kidney and upper ureteral stones. All procedures were performed by experienced urologists using standard techniques for laser lithotripsy. Laser settings, such as pulse energy and frequency, were adjusted according to stone characteristics and the surgeon's judgment to optimize treatment efficacy and safety.
Study: NCT06671522

Intervention type: OTHER
Intervention: Survey
Description: It is a qualitatative research. Only a survey.
Study: NCT06671405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0780
Description: Dose 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0780
Description: Dose 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: * Period 2 (itraconazole administration only).~* Period 3 (AZD0780 + itraconazole administration).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Description: * Period 2 (carbamazepine administration only).~* Period 3 (AZD0780 + carbamazepine administration only).
Study: NCT06671418

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Primary percutaneous stenting (PPS)
Description: PPS bridging malignant hilar biliary obstruction with self-expandable uncovered metal stents without crossing the ampulla and without leaving an external drain. The procedure is performed by an interventional radiologist who has performed at least 5 PPS procedures.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endoscopic biliary drainage
Description: EBD according to the American Society for Gastrointestinal Endoscopy (ASGE) guidelines of 2021. The procedure is performed by a gastro-enterologist who is experienced in performing EBD in patients with a MHBO.
Study: NCT06671951

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Focal Vibration
Description: Focal vibration is a 3x3 electrode placed on the athlete's muscle belly, and emits a high frequency vibration (150Hz) to stimulate the muscle spindle and generate greater muscle activation.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham focal vibration
Description: Is a focal vibration intervention but without conctact in the athelte's skin. Doing this we got a sham therapy
Study: NCT06671197

Intervention type: DEVICE
Intervention: Pulmonary vein isolation
Description: Pulsed field ablation

Intervention type: DEVICE
Intervention: Pulmonary vein isolation+posterior left atrial wall line
Description: Pulsed field ablation

Intervention type: DEVICE
Intervention: Pulmonary vein isolation+posterior left atrial wall line+superior vena cava isolation
Description: Pulsed field ablation
Study: NCT06672367

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Balance training group
Description: It includes participants receiving balance training for mild cognitive impairment.~Balance training~Walking on a flat surface at the beginning of each session for 5-10 minutes Perform different static and dynamic balance exercises along with cognitive tasks.~Static standing with feet together with eyes open and closed Semi-tandem stand and tandem stand Forward and backward weight shift exercises Counting backwards by threes, Naming object or animals, Recalling a short sequence of numbers or words.~Side stepping, marching, forward and backward walking Hip extension and abduction Cognitive task includes word association or simple math problems. Standing on one leg Relaxation and breathing exercises including deep inhaling and exhaling or walking slowly at the end of each session for 5-10 minutes During training sessions, balance activities and cognitive tasks will be implemented simultaneously.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Balance training combined with gaze stability exercises
Description: It includes participants receiving balance training combined with gaze stability exercises for mild cognitive impairment.~Balance training~Walking on a flat surface at the beginning of each session for 5-10 minutes Perform different static and dynamic balance exercises along with cognitive tasks.~Static standing with feet together with eyes open and closed Semi-tandem stand and tandem stand Forward and backward weight shift exercises Counting backwards by threes, Naming object or animals, Recalling a short sequence of numbers or words.~Side stepping, marching, forward and backward walking Hip extension and abduction Cognitive task includes word association or simple math problems. Standing on one leg Relaxation and breathing exercises including deep inhaling and exhaling or walking slowly at the end of each session for 5-10 minutes During training sessions, balance activities and cognitive tasks will be implemented simultaneously.~Gaze stability exercises~Visual tracking exercises
Study: NCT06671769

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Heart Health Supplement
Description: This is a natural heart health supplement in powdered format, chocolate flavor where participants will take a daily dose.
Study: NCT06673251

Intervention type: OTHER
Intervention: motor and sensory assessments, surveys
Description: It does not include any intervention. Only evaluation will be made.

Intervention type: OTHER
Intervention: motor and sensory assessments, surveys
Description: It does not include any intervention. Only evaluation will be made.
Study: NCT06421246

Intervention type: BEHAVIORAL
Intervention: Staff-facing screen
Description: Activity will be monitored before and after the introduction of a staff-facing screen
Study: NCT06039917

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AI based automatic surveillance (AS) system (ENDOANGEL-AS)
Description: An automatic surveillance (AS) system accurately identify patients with gastric premalignant lesions, assign surveillance intervals for different risks of patients and proactively follow up with patients at certain times.
Study: NCT05652764

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Orem's Self-Care Deficit Theory Based Nursing Interventions for Immunotherapy Treated Cancer Patients
Description: In this study, face-to-face patient education, giving patient education booklet, preparation of symptom management card, face-to-face and telephone counseling initiatives were planned to the experimental group.
Study: NCT06039917

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manually remind the patients
Description: Medical staff remind patients to review manually.
Study: NCT05774691

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Protamine sulfate
Description: Routine protamine administration in a ratio of 1 mg per 100 IU of unfractionated heparin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Protamine sulfate
Description: Selective protamine administration, in case of (threatening) bleeding
Study: NCT05664685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optimized bismuth quadruple therapy
Description: Scheme that have high dosage of amoxicillin, metronidazole and omeprazole, with bismuth. The rationale of this scheme is that in Chile, amoxicillin resistance is low, clinical metronidazole is low in the doses used and the high doses ob Proton Pump Inhibitor enhanced the antimicrobial drugs
Study: NCT04990232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra or rhIFNγ
Description: In hyper-inflammation anakinra three times daily (every eight hours) for 15 days and sc 0.5 ml N/S 0.9% every other day for 15 days. In immunoparalysis IV 20 ml N/S 0.9% (10ml for patients with creatinine clearance lower than 30ml/min) three times daily (every eight hours) for 15 days and sc rhIFNγ every other day for 15 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 20ml (10ml for patients with creatinine clearance lower than 30ml/min) intravenous (IV) 0.9% saline (N/S) three times daily (every eight hours) for 15 days and 0.5 ml subcutaneous (sc) 1ml 0.9% N/S every other day for a total of 15 days
Study: NCT06526208

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MB-IMP
Description: MB-IMP is a marijuana-based investigational medical product. It contains a 23:1 ratio of CBD to THC, is an oil-based tincture that is taken orally.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Does not contain CBD or THC
Study: NCT06367062

Intervention type: OTHER
Intervention: MRI
Description: MRI is used to assess of brain development.

Intervention type: OTHER
Intervention: MRI
Description: MRI is used to assess of brain development.
Study: NCT06276153

Intervention type: OTHER
Intervention: no interventions
Description: retrospective registry cohort with no other specific interventions
Study: NCT06367062

Intervention type: OTHER
Intervention: MRI
Description: MRI is used to assess of brain development.
Study: NCT06010121

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Liposomal Vitamin D
Description: 2000 IU of cholecalciferol in liposomal formulation

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Vitamin D
Description: 2000 IU of cholecalciferol in traditional formulation
Study: NCT05664685

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Standard eradication therapy using omeprazole, clarithromycin and amoxicillin
Study: NCT05768295

Intervention type: DEVICE
Group type: OTHER
Intervention: Axiom BL X3
Description: collecting data on the use of Axiom BL X3 and patient satisfaction
Study: NCT05632939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASKB589 +CAPOX+Sintilimab
Description: Oxaliplatin: intravenous infusion, 130mg/m2, infusion for more than 3h, every 3 weeks for a cycle, infusion 6 cycles; Capecitabine: oral administration, 1000mg/m2, 2 times, 14 days, 7 days rest, every 3 weeks for a cycle; Sintilimab was administered intravenously at 200mg. The drug was administered once every 3 weeks, and the longest cumulative duration was 2 years.~ASKB589 is administered intravenously at a fixed dose. the drug was given once every 3 weeks for a cycle, with the longest cumulative duration of 2 years.
Study: NCT03630081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WCK 4282 (FEP-TAZ) 4 g
Description: WCK 4282 (FEP-TAZ) 4 g \[2 g FEP and 2 g TAZ\] IV q8h, infused over 90 min

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem
Description: 1 g IV q8h, infused over 45 min

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ciprofloxacin 500 mg Optional Oral Switch
Description: ciprofloxacin 500 mg PO q12h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ciprofloxacin 500 mg Optional Oral Switch
Description: ciprofloxacin 500 mg PO q12h

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Infusion of normal saline
Description: Infusion of normal saline over 45 min